| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/02/2002 | EP1201136A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/02/2002 | EP1200616A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 05/02/2002 | EP1200608A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 05/02/2002 | EP1200602A1 Dsp-11 dual-specificity map kinase phophatase |
| 05/02/2002 | EP1200599A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200581A1 Truncated egf receptor |
| 05/02/2002 | EP1200572A1 Antisense modulation of liver glycogen phosphorylase expression |
| 05/02/2002 | EP1200570A1 Antisense modulation of p13 kinase p110 delta expression |
| 05/02/2002 | EP1200560A1 Melanin-concentrating hormone receptor |
| 05/02/2002 | EP1200559A2 Muscle cells and their use in cardiac repair |
| 05/02/2002 | EP1200555A1 Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
| 05/02/2002 | EP1200476A1 Antitumor antibodies, proteins, and uses thereof |
| 05/02/2002 | EP1200472A1 Odorant receptors |
| 05/02/2002 | EP1200469A2 Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases |
| 05/02/2002 | EP1200468A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF i STAPHYLOCOCCUS AUREUS /i ELONGATION FACTOR P |
| 05/02/2002 | EP1200462A2 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 05/02/2002 | EP1200458A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 05/02/2002 | EP1200456A1 Antisense modulation of pten expression |
| 05/02/2002 | EP1200455A1 Enzyme catalyzed therapeutic activation |
| 05/02/2002 | EP1200451A1 Radiolabelled bisphosphonates and method |
| 05/02/2002 | EP1200447A1 Oxazinocarbazoles for the treatment of cns diseases |
| 05/02/2002 | EP1200444A1 Novel xanthone compounds, their preparation and use as medicament |
| 05/02/2002 | EP1200443A1 Aromatic esters of camptothecins and methods to treat cancers |
| 05/02/2002 | EP1200440A1 Quinuclidine derivatives for treatment of neurological disorders |
| 05/02/2002 | EP1200435A1 Purine derivatives inhibitors of tyrosine protein kinase syk |
| 05/02/2002 | EP1200433A1 C-6 RING-SUBSTITUTED PYRIDO 1,2- i a /i ]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS |
| 05/02/2002 | EP1200431A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 05/02/2002 | EP1200427A2 Small molecule modulators of g protein-coupled receptor six (gpr6) |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200419A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 05/02/2002 | EP1200415A1 Diamino-1,2,4-triazole-carboxylic acid derivatives as gsk-3 inhibitors |
| 05/02/2002 | EP1200412A2 Imidazole antiproliferative agents |
| 05/02/2002 | EP1200406A1 Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor |
| 05/02/2002 | EP1200405A1 Benzenamine derivatives as anti-coagulants |
| 05/02/2002 | EP1200402A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 05/02/2002 | EP1200398A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 05/02/2002 | EP1200396A1 Naphthylsulfonic acids and related compounds as glucose uptake agonists |
| 05/02/2002 | EP1200395A1 Urea derivatives as inhibitors of ccr-3 receptor |
| 05/02/2002 | EP1200320A1 Valve with a two-component seal |
| 05/02/2002 | EP1200133A1 Manipulation of tissue or organ type using the notch pathway |
| 05/02/2002 | EP1200130A2 Methods for treating therapy-resistant tumors |
| 05/02/2002 | EP1200127A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 05/02/2002 | EP1200119A2 Method for down-regulating gdf-8 activity |
| 05/02/2002 | EP1200118A1 A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug |
| 05/02/2002 | EP1200117A2 Lipoprotein lipase (lpl) variant therapeutics |
| 05/02/2002 | EP1200116A2 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 05/02/2002 | EP1200114A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/02/2002 | EP1200111A1 Compositions for the treatment of the catabolic state of prolonged critical illness |
| 05/02/2002 | EP1200110A1 In vivo induction for enhanced function of isolated hepatocytes |
| 05/02/2002 | EP1200108A1 Use of ginkgo extract |
| 05/02/2002 | EP1200103A1 Xenon as nmda antagonist |
| 05/02/2002 | EP1200099A1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 05/02/2002 | EP1200097A2 Method for controlling the fidelity and the execution of reverse transcriptase by incorporating and polymerising nucleotide analogues accepted as substrates of the reverse transcription response without blocking its elongation |
| 05/02/2002 | EP1200094A1 Ophthalmic compositions containing antibiotics and nsaids |
| 05/02/2002 | EP1200093A2 Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |
| 05/02/2002 | EP1200086A2 Methods for treating or preventing pain and anxiety |
| 05/02/2002 | EP1200084A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 05/02/2002 | EP1200078A1 Compositions and methods for promoting nerve regeneration |
| 05/02/2002 | EP1200074A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 05/02/2002 | EP1200073A2 SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 05/02/2002 | EP1200072A2 Method of treating psychotic disorders |
| 05/02/2002 | EP1200068A2 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 05/02/2002 | EP1200064A1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
| 05/02/2002 | EP1200040A1 Two-component composition for cosmetic or pharmaceutical use |
| 05/02/2002 | EP1173192A4 Methods and compositions for targeted drug delivery |
| 05/02/2002 | EP1146875A4 Myt1 kinase inhibitors |
| 05/02/2002 | EP1089726B1 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 05/02/2002 | EP0941097B1 Use of mixtures of active substances for the production of hypocholesteremic agents |
| 05/02/2002 | EP0931086B1 Tetrahydronaphthalene derivatives and their therapeutic use |
| 05/02/2002 | EP0885004B1 Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
| 05/02/2002 | EP0841907B1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 05/02/2002 | EP0840740B1 New inhibitors of platelet aggregation |
| 05/02/2002 | EP0724884B1 Side effect inhibitor for cancer therapy |
| 05/02/2002 | DE10052333A1 Neue Sulfooxybenzamide New Sulfooxybenzamide |
| 05/02/2002 | CA2689012A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2427024A1 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | CA2427005A1 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | CA2426902A1 Methods of improving central nervous system functioning |
| 05/02/2002 | CA2426896A1 Compositions and methods for the discovery and selection of biological information |
| 05/02/2002 | CA2426895A1 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents |
| 05/02/2002 | CA2426773A1 Beta-substituted beta-aminoethyl phosphonates |
| 05/02/2002 | CA2426767A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | CA2426736A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | CA2426674A1 Agent for preventing or treating portal hypertension |
| 05/02/2002 | CA2426672A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 05/02/2002 | CA2426465A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/02/2002 | CA2426463A1 Novel aggrecanase molecules |
| 05/02/2002 | CA2426360A1 Enhancers for microbiological disinfection and targeted apoptosis |
| 05/02/2002 | CA2426203A1 Anticancer agents based on regulation of protein prenylation |
| 05/02/2002 | CA2426007A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/02/2002 | CA2425897A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | CA2425596A1 Methods of therapy for hiv infection |
| 05/02/2002 | CA2425288A1 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | CA2425283A1 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2425280A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |